nodes	percent_of_prediction	percent_of_DWPC	metapath
Risedronate—PTGS2—prostate cancer	0.438	1	CbGaD
Risedronate—FDPS—prostate gland—prostate cancer	0.00504	0.159	CbGeAlD
Risedronate—FDPS—seminal vesicle—prostate cancer	0.00426	0.134	CbGeAlD
Risedronate—FDPS—renal system—prostate cancer	0.00343	0.108	CbGeAlD
Risedronate—FDPS—urethra—prostate cancer	0.00337	0.106	CbGeAlD
Risedronate—FDPS—bone marrow—prostate cancer	0.0026	0.0818	CbGeAlD
Risedronate—FDPS—testis—prostate cancer	0.00222	0.0699	CbGeAlD
Risedronate—Histamine Phosphate—SLC22A3—prostate cancer	0.00202	0.508	CrCbGaD
Risedronate—PTGS2—prostate gland—prostate cancer	0.00193	0.0609	CbGeAlD
Risedronate—PTGS2—seminal vesicle—prostate cancer	0.00163	0.0515	CbGeAlD
Risedronate—FDPS—lymph node—prostate cancer	0.00161	0.0507	CbGeAlD
Risedronate—Histamine Phosphate—SLC22A1—prostate cancer	0.00145	0.364	CrCbGaD
Risedronate—PTGS2—epithelium—prostate cancer	0.00142	0.0447	CbGeAlD
Risedronate—PTGS2—renal system—prostate cancer	0.00132	0.0415	CbGeAlD
Risedronate—PTGS2—urethra—prostate cancer	0.00129	0.0407	CbGeAlD
Risedronate—PTGS2—bone marrow—prostate cancer	0.000995	0.0314	CbGeAlD
Risedronate—PTGS2—lymph node—prostate cancer	0.000617	0.0194	CbGeAlD
Risedronate—Histamine Phosphate—CYP3A4—prostate cancer	0.000505	0.127	CrCbGaD
Risedronate—Urinary tract infection—Epirubicin—prostate cancer	9.99e-05	0.000251	CcSEcCtD
Risedronate—Dizziness—Estradiol—prostate cancer	9.98e-05	0.000251	CcSEcCtD
Risedronate—Hypertension—Capecitabine—prostate cancer	9.96e-05	0.00025	CcSEcCtD
Risedronate—Dry mouth—Docetaxel—prostate cancer	9.92e-05	0.000249	CcSEcCtD
Risedronate—Upper respiratory tract infection—Doxorubicin—prostate cancer	9.91e-05	0.000249	CcSEcCtD
Risedronate—Chest pain—Capecitabine—prostate cancer	9.82e-05	0.000247	CcSEcCtD
Risedronate—Arthralgia—Capecitabine—prostate cancer	9.82e-05	0.000247	CcSEcCtD
Risedronate—Myalgia—Capecitabine—prostate cancer	9.82e-05	0.000247	CcSEcCtD
Risedronate—Anxiety—Capecitabine—prostate cancer	9.78e-05	0.000246	CcSEcCtD
Risedronate—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	9.75e-05	0.000245	CcSEcCtD
Risedronate—Hepatobiliary disease—Epirubicin—prostate cancer	9.72e-05	0.000244	CcSEcCtD
Risedronate—Infection—Docetaxel—prostate cancer	9.66e-05	0.000243	CcSEcCtD
Risedronate—Sinusitis—Epirubicin—prostate cancer	9.64e-05	0.000242	CcSEcCtD
Risedronate—Diarrhoea—Mitoxantrone—prostate cancer	9.62e-05	0.000242	CcSEcCtD
Risedronate—Dry mouth—Capecitabine—prostate cancer	9.6e-05	0.000241	CcSEcCtD
Risedronate—Vomiting—Estradiol—prostate cancer	9.59e-05	0.000241	CcSEcCtD
Risedronate—Pneumonia—Doxorubicin—prostate cancer	9.57e-05	0.00024	CcSEcCtD
Risedronate—Gastrointestinal pain—Etoposide—prostate cancer	9.56e-05	0.00024	CcSEcCtD
Risedronate—Shock—Docetaxel—prostate cancer	9.56e-05	0.00024	CcSEcCtD
Risedronate—Nervous system disorder—Docetaxel—prostate cancer	9.53e-05	0.00024	CcSEcCtD
Risedronate—Rash—Estradiol—prostate cancer	9.51e-05	0.000239	CcSEcCtD
Risedronate—Infestation NOS—Doxorubicin—prostate cancer	9.51e-05	0.000239	CcSEcCtD
Risedronate—Infestation—Doxorubicin—prostate cancer	9.51e-05	0.000239	CcSEcCtD
Risedronate—Dermatitis—Estradiol—prostate cancer	9.51e-05	0.000239	CcSEcCtD
Risedronate—Anaemia—Prednisone—prostate cancer	9.49e-05	0.000239	CcSEcCtD
Risedronate—Headache—Estradiol—prostate cancer	9.45e-05	0.000238	CcSEcCtD
Risedronate—Skin disorder—Docetaxel—prostate cancer	9.44e-05	0.000237	CcSEcCtD
Risedronate—Angioedema—Prednisone—prostate cancer	9.38e-05	0.000236	CcSEcCtD
Risedronate—Infection—Capecitabine—prostate cancer	9.35e-05	0.000235	CcSEcCtD
Risedronate—Urticaria—Etoposide—prostate cancer	9.29e-05	0.000233	CcSEcCtD
Risedronate—Haemoglobin—Epirubicin—prostate cancer	9.27e-05	0.000233	CcSEcCtD
Risedronate—Shock—Capecitabine—prostate cancer	9.26e-05	0.000233	CcSEcCtD
Risedronate—Rhinitis—Epirubicin—prostate cancer	9.25e-05	0.000232	CcSEcCtD
Risedronate—Abdominal pain—Etoposide—prostate cancer	9.25e-05	0.000232	CcSEcCtD
Risedronate—Body temperature increased—Etoposide—prostate cancer	9.25e-05	0.000232	CcSEcCtD
Risedronate—Conjunctivitis—Doxorubicin—prostate cancer	9.25e-05	0.000232	CcSEcCtD
Risedronate—Urinary tract infection—Doxorubicin—prostate cancer	9.25e-05	0.000232	CcSEcCtD
Risedronate—Nervous system disorder—Capecitabine—prostate cancer	9.23e-05	0.000232	CcSEcCtD
Risedronate—Vertigo—Prednisone—prostate cancer	9.23e-05	0.000232	CcSEcCtD
Risedronate—Haemorrhage—Epirubicin—prostate cancer	9.23e-05	0.000232	CcSEcCtD
Risedronate—Syncope—Prednisone—prostate cancer	9.21e-05	0.000231	CcSEcCtD
Risedronate—Pharyngitis—Epirubicin—prostate cancer	9.16e-05	0.00023	CcSEcCtD
Risedronate—Skin disorder—Capecitabine—prostate cancer	9.14e-05	0.00023	CcSEcCtD
Risedronate—Urinary tract disorder—Epirubicin—prostate cancer	9.11e-05	0.000229	CcSEcCtD
Risedronate—Oedema peripheral—Epirubicin—prostate cancer	9.09e-05	0.000228	CcSEcCtD
Risedronate—Connective tissue disorder—Epirubicin—prostate cancer	9.07e-05	0.000228	CcSEcCtD
Risedronate—Urethral disorder—Epirubicin—prostate cancer	9.05e-05	0.000227	CcSEcCtD
Risedronate—Loss of consciousness—Prednisone—prostate cancer	9.03e-05	0.000227	CcSEcCtD
Risedronate—Hepatobiliary disease—Doxorubicin—prostate cancer	9e-05	0.000226	CcSEcCtD
Risedronate—Nausea—Estradiol—prostate cancer	8.96e-05	0.000225	CcSEcCtD
Risedronate—Vomiting—Mitoxantrone—prostate cancer	8.94e-05	0.000225	CcSEcCtD
Risedronate—Sinusitis—Doxorubicin—prostate cancer	8.92e-05	0.000224	CcSEcCtD
Risedronate—Hypertension—Prednisone—prostate cancer	8.87e-05	0.000223	CcSEcCtD
Risedronate—Rash—Mitoxantrone—prostate cancer	8.87e-05	0.000223	CcSEcCtD
Risedronate—Dermatitis—Mitoxantrone—prostate cancer	8.86e-05	0.000223	CcSEcCtD
Risedronate—Musculoskeletal discomfort—Docetaxel—prostate cancer	8.86e-05	0.000223	CcSEcCtD
Risedronate—Headache—Mitoxantrone—prostate cancer	8.81e-05	0.000221	CcSEcCtD
Risedronate—Insomnia—Docetaxel—prostate cancer	8.79e-05	0.000221	CcSEcCtD
Risedronate—Myalgia—Prednisone—prostate cancer	8.74e-05	0.00022	CcSEcCtD
Risedronate—Arthralgia—Prednisone—prostate cancer	8.74e-05	0.00022	CcSEcCtD
Risedronate—Paraesthesia—Docetaxel—prostate cancer	8.73e-05	0.000219	CcSEcCtD
Risedronate—Anxiety—Prednisone—prostate cancer	8.71e-05	0.000219	CcSEcCtD
Risedronate—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	8.68e-05	0.000218	CcSEcCtD
Risedronate—Dyspnoea—Docetaxel—prostate cancer	8.67e-05	0.000218	CcSEcCtD
Risedronate—Eye disorder—Epirubicin—prostate cancer	8.62e-05	0.000217	CcSEcCtD
Risedronate—Hypersensitivity—Etoposide—prostate cancer	8.62e-05	0.000217	CcSEcCtD
Risedronate—Tinnitus—Epirubicin—prostate cancer	8.6e-05	0.000216	CcSEcCtD
Risedronate—Haemoglobin—Doxorubicin—prostate cancer	8.58e-05	0.000216	CcSEcCtD
Risedronate—Musculoskeletal discomfort—Capecitabine—prostate cancer	8.57e-05	0.000215	CcSEcCtD
Risedronate—Cardiac disorder—Epirubicin—prostate cancer	8.56e-05	0.000215	CcSEcCtD
Risedronate—Rhinitis—Doxorubicin—prostate cancer	8.56e-05	0.000215	CcSEcCtD
Risedronate—Dyspepsia—Docetaxel—prostate cancer	8.56e-05	0.000215	CcSEcCtD
Risedronate—Haemorrhage—Doxorubicin—prostate cancer	8.54e-05	0.000215	CcSEcCtD
Risedronate—Insomnia—Capecitabine—prostate cancer	8.51e-05	0.000214	CcSEcCtD
Risedronate—Pharyngitis—Doxorubicin—prostate cancer	8.47e-05	0.000213	CcSEcCtD
Risedronate—Paraesthesia—Capecitabine—prostate cancer	8.45e-05	0.000212	CcSEcCtD
Risedronate—Urinary tract disorder—Doxorubicin—prostate cancer	8.43e-05	0.000212	CcSEcCtD
Risedronate—Oedema peripheral—Doxorubicin—prostate cancer	8.41e-05	0.000211	CcSEcCtD
Risedronate—Gastrointestinal disorder—Docetaxel—prostate cancer	8.39e-05	0.000211	CcSEcCtD
Risedronate—Asthenia—Etoposide—prostate cancer	8.39e-05	0.000211	CcSEcCtD
Risedronate—Connective tissue disorder—Doxorubicin—prostate cancer	8.39e-05	0.000211	CcSEcCtD
Risedronate—Dyspnoea—Capecitabine—prostate cancer	8.39e-05	0.000211	CcSEcCtD
Risedronate—Fatigue—Docetaxel—prostate cancer	8.38e-05	0.000211	CcSEcCtD
Risedronate—Angiopathy—Epirubicin—prostate cancer	8.37e-05	0.00021	CcSEcCtD
Risedronate—Urethral disorder—Doxorubicin—prostate cancer	8.37e-05	0.00021	CcSEcCtD
Risedronate—Nausea—Mitoxantrone—prostate cancer	8.35e-05	0.00021	CcSEcCtD
Risedronate—Immune system disorder—Epirubicin—prostate cancer	8.33e-05	0.000209	CcSEcCtD
Risedronate—Infection—Prednisone—prostate cancer	8.33e-05	0.000209	CcSEcCtD
Risedronate—Mediastinal disorder—Epirubicin—prostate cancer	8.32e-05	0.000209	CcSEcCtD
Risedronate—Constipation—Docetaxel—prostate cancer	8.31e-05	0.000209	CcSEcCtD
Risedronate—Pain—Docetaxel—prostate cancer	8.31e-05	0.000209	CcSEcCtD
Risedronate—Dyspepsia—Capecitabine—prostate cancer	8.28e-05	0.000208	CcSEcCtD
Risedronate—Pruritus—Etoposide—prostate cancer	8.27e-05	0.000208	CcSEcCtD
Risedronate—Shock—Prednisone—prostate cancer	8.25e-05	0.000207	CcSEcCtD
Risedronate—Arrhythmia—Epirubicin—prostate cancer	8.24e-05	0.000207	CcSEcCtD
Risedronate—Nervous system disorder—Prednisone—prostate cancer	8.22e-05	0.000207	CcSEcCtD
Risedronate—Skin disorder—Prednisone—prostate cancer	8.14e-05	0.000205	CcSEcCtD
Risedronate—Gastrointestinal disorder—Capecitabine—prostate cancer	8.12e-05	0.000204	CcSEcCtD
Risedronate—Fatigue—Capecitabine—prostate cancer	8.11e-05	0.000204	CcSEcCtD
Risedronate—Mental disorder—Epirubicin—prostate cancer	8.08e-05	0.000203	CcSEcCtD
Risedronate—Pain—Capecitabine—prostate cancer	8.05e-05	0.000202	CcSEcCtD
Risedronate—Constipation—Capecitabine—prostate cancer	8.05e-05	0.000202	CcSEcCtD
Risedronate—Malnutrition—Epirubicin—prostate cancer	8.03e-05	0.000202	CcSEcCtD
Risedronate—Diarrhoea—Etoposide—prostate cancer	8e-05	0.000201	CcSEcCtD
Risedronate—Eye disorder—Doxorubicin—prostate cancer	7.98e-05	0.0002	CcSEcCtD
Risedronate—Tinnitus—Doxorubicin—prostate cancer	7.96e-05	0.0002	CcSEcCtD
Risedronate—Gastrointestinal pain—Docetaxel—prostate cancer	7.95e-05	0.0002	CcSEcCtD
Risedronate—Cardiac disorder—Doxorubicin—prostate cancer	7.92e-05	0.000199	CcSEcCtD
Risedronate—Flatulence—Epirubicin—prostate cancer	7.92e-05	0.000199	CcSEcCtD
Risedronate—Back pain—Epirubicin—prostate cancer	7.77e-05	0.000195	CcSEcCtD
Risedronate—Angiopathy—Doxorubicin—prostate cancer	7.75e-05	0.000195	CcSEcCtD
Risedronate—Dizziness—Etoposide—prostate cancer	7.73e-05	0.000194	CcSEcCtD
Risedronate—Muscle spasms—Epirubicin—prostate cancer	7.72e-05	0.000194	CcSEcCtD
Risedronate—Immune system disorder—Doxorubicin—prostate cancer	7.71e-05	0.000194	CcSEcCtD
Risedronate—Gastrointestinal pain—Capecitabine—prostate cancer	7.7e-05	0.000193	CcSEcCtD
Risedronate—Mediastinal disorder—Doxorubicin—prostate cancer	7.69e-05	0.000193	CcSEcCtD
Risedronate—Body temperature increased—Docetaxel—prostate cancer	7.68e-05	0.000193	CcSEcCtD
Risedronate—Abdominal pain—Docetaxel—prostate cancer	7.68e-05	0.000193	CcSEcCtD
Risedronate—Musculoskeletal discomfort—Prednisone—prostate cancer	7.64e-05	0.000192	CcSEcCtD
Risedronate—Arrhythmia—Doxorubicin—prostate cancer	7.63e-05	0.000192	CcSEcCtD
Risedronate—Insomnia—Prednisone—prostate cancer	7.58e-05	0.000191	CcSEcCtD
Risedronate—Paraesthesia—Prednisone—prostate cancer	7.53e-05	0.000189	CcSEcCtD
Risedronate—PTGS2—Disease—CTBP2—prostate cancer	7.48e-05	0.000585	CbGpPWpGaD
Risedronate—PTGS2—Disease—HSD17B1—prostate cancer	7.48e-05	0.000585	CbGpPWpGaD
Risedronate—PTGS2—Disease—DNAJC3—prostate cancer	7.48e-05	0.000585	CbGpPWpGaD
Risedronate—Mental disorder—Doxorubicin—prostate cancer	7.48e-05	0.000188	CcSEcCtD
Risedronate—Urticaria—Capecitabine—prostate cancer	7.48e-05	0.000188	CcSEcCtD
Risedronate—Body temperature increased—Capecitabine—prostate cancer	7.44e-05	0.000187	CcSEcCtD
Risedronate—Abdominal pain—Capecitabine—prostate cancer	7.44e-05	0.000187	CcSEcCtD
Risedronate—Vomiting—Etoposide—prostate cancer	7.44e-05	0.000187	CcSEcCtD
Risedronate—Malnutrition—Doxorubicin—prostate cancer	7.43e-05	0.000187	CcSEcCtD
Risedronate—Anaemia—Epirubicin—prostate cancer	7.42e-05	0.000187	CcSEcCtD
Risedronate—FDPS—Metabolism—GSTM1—prostate cancer	7.42e-05	0.000581	CbGpPWpGaD
Risedronate—Dyspepsia—Prednisone—prostate cancer	7.38e-05	0.000185	CcSEcCtD
Risedronate—Rash—Etoposide—prostate cancer	7.37e-05	0.000185	CcSEcCtD
Risedronate—PTGS2—Metabolism—UGT2B15—prostate cancer	7.37e-05	0.000577	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—UGT2B17—prostate cancer	7.37e-05	0.000577	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—GRHPR—prostate cancer	7.37e-05	0.000577	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—CKMT2—prostate cancer	7.37e-05	0.000577	CbGpPWpGaD
Risedronate—Dermatitis—Etoposide—prostate cancer	7.37e-05	0.000185	CcSEcCtD
Risedronate—PTGS2—Spinal Cord Injury—CASP3—prostate cancer	7.35e-05	0.000575	CbGpPWpGaD
Risedronate—PTGS2—Spinal Cord Injury—IL2—prostate cancer	7.34e-05	0.000575	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—BAD—prostate cancer	7.33e-05	0.000573	CbGpPWpGaD
Risedronate—Headache—Etoposide—prostate cancer	7.33e-05	0.000184	CcSEcCtD
Risedronate—Flatulence—Doxorubicin—prostate cancer	7.32e-05	0.000184	CcSEcCtD
Risedronate—FDPS—Metabolism—LPL—prostate cancer	7.28e-05	0.00057	CbGpPWpGaD
Risedronate—Fatigue—Prednisone—prostate cancer	7.23e-05	0.000182	CcSEcCtD
Risedronate—Vertigo—Epirubicin—prostate cancer	7.22e-05	0.000181	CcSEcCtD
Risedronate—Syncope—Epirubicin—prostate cancer	7.2e-05	0.000181	CcSEcCtD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—SULT2A1—prostate cancer	7.2e-05	0.000564	CbGpPWpGaD
Risedronate—Back pain—Doxorubicin—prostate cancer	7.19e-05	0.000181	CcSEcCtD
Risedronate—Constipation—Prednisone—prostate cancer	7.17e-05	0.00018	CcSEcCtD
Risedronate—Hypersensitivity—Docetaxel—prostate cancer	7.16e-05	0.00018	CcSEcCtD
Risedronate—PTGS2—Spinal Cord Injury—CCND1—prostate cancer	7.16e-05	0.00056	CbGpPWpGaD
Risedronate—Muscle spasms—Doxorubicin—prostate cancer	7.15e-05	0.00018	CcSEcCtD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—APC—prostate cancer	7.1e-05	0.000555	CbGpPWpGaD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—MED12—prostate cancer	7.09e-05	0.000554	CbGpPWpGaD
Risedronate—Loss of consciousness—Epirubicin—prostate cancer	7.06e-05	0.000177	CcSEcCtD
Risedronate—FDPS—Metabolism—CYP1A1—prostate cancer	7.03e-05	0.000551	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—EGF—prostate cancer	7.02e-05	0.000549	CbGpPWpGaD
Risedronate—Cough—Epirubicin—prostate cancer	7.01e-05	0.000176	CcSEcCtD
Risedronate—FDPS—Metabolism—ERCC2—prostate cancer	6.98e-05	0.000546	CbGpPWpGaD
Risedronate—Asthenia—Docetaxel—prostate cancer	6.97e-05	0.000175	CcSEcCtD
Risedronate—PTGS2—C-MYB transcription factor network—KRAS—prostate cancer	6.96e-05	0.000545	CbGpPWpGaD
Risedronate—PTGS2—Spinal Cord Injury—MMP9—prostate cancer	6.95e-05	0.000544	CbGpPWpGaD
Risedronate—Nausea—Etoposide—prostate cancer	6.95e-05	0.000175	CcSEcCtD
Risedronate—Hypertension—Epirubicin—prostate cancer	6.94e-05	0.000174	CcSEcCtD
Risedronate—Hypersensitivity—Capecitabine—prostate cancer	6.93e-05	0.000174	CcSEcCtD
Risedronate—PTGS2—Metabolism—SULT2B1—prostate cancer	6.93e-05	0.000542	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—RFK—prostate cancer	6.93e-05	0.000542	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—GSTM3—prostate cancer	6.93e-05	0.000542	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—NAGLU—prostate cancer	6.93e-05	0.000542	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—PGAM2—prostate cancer	6.93e-05	0.000542	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—AOX1—prostate cancer	6.93e-05	0.000542	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—MBTPS1—prostate cancer	6.93e-05	0.000542	CbGpPWpGaD
Risedronate—Pruritus—Docetaxel—prostate cancer	6.88e-05	0.000173	CcSEcCtD
Risedronate—Anaemia—Doxorubicin—prostate cancer	6.87e-05	0.000173	CcSEcCtD
Risedronate—Gastrointestinal pain—Prednisone—prostate cancer	6.85e-05	0.000172	CcSEcCtD
Risedronate—Myalgia—Epirubicin—prostate cancer	6.84e-05	0.000172	CcSEcCtD
Risedronate—Arthralgia—Epirubicin—prostate cancer	6.84e-05	0.000172	CcSEcCtD
Risedronate—Chest pain—Epirubicin—prostate cancer	6.84e-05	0.000172	CcSEcCtD
Risedronate—Anxiety—Epirubicin—prostate cancer	6.82e-05	0.000171	CcSEcCtD
Risedronate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	6.79e-05	0.000171	CcSEcCtD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—NCOA3—prostate cancer	6.77e-05	0.00053	CbGpPWpGaD
Risedronate—Asthenia—Capecitabine—prostate cancer	6.75e-05	0.00017	CcSEcCtD
Risedronate—Dry mouth—Epirubicin—prostate cancer	6.69e-05	0.000168	CcSEcCtD
Risedronate—Vertigo—Doxorubicin—prostate cancer	6.68e-05	0.000168	CcSEcCtD
Risedronate—PTGS2—Disease—IL17RD—prostate cancer	6.67e-05	0.000522	CbGpPWpGaD
Risedronate—PTGS2—Disease—B4GALT4—prostate cancer	6.67e-05	0.000522	CbGpPWpGaD
Risedronate—Syncope—Doxorubicin—prostate cancer	6.67e-05	0.000167	CcSEcCtD
Risedronate—Urticaria—Prednisone—prostate cancer	6.66e-05	0.000167	CcSEcCtD
Risedronate—Pruritus—Capecitabine—prostate cancer	6.66e-05	0.000167	CcSEcCtD
Risedronate—Diarrhoea—Docetaxel—prostate cancer	6.65e-05	0.000167	CcSEcCtD
Risedronate—Body temperature increased—Prednisone—prostate cancer	6.63e-05	0.000167	CcSEcCtD
Risedronate—Abdominal pain—Prednisone—prostate cancer	6.63e-05	0.000167	CcSEcCtD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—CREBBP—prostate cancer	6.58e-05	0.000515	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—AMACR—prostate cancer	6.57e-05	0.000514	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—CYP3A43—prostate cancer	6.57e-05	0.000514	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—DEGS1—prostate cancer	6.57e-05	0.000514	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—NAT1—prostate cancer	6.57e-05	0.000514	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—SRD5A2—prostate cancer	6.57e-05	0.000514	CbGpPWpGaD
Risedronate—FDPS—Metabolism—MTHFR—prostate cancer	6.56e-05	0.000513	CbGpPWpGaD
Risedronate—Loss of consciousness—Doxorubicin—prostate cancer	6.53e-05	0.000164	CcSEcCtD
Risedronate—Infection—Epirubicin—prostate cancer	6.51e-05	0.000164	CcSEcCtD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—IGF1—prostate cancer	6.5e-05	0.000508	CbGpPWpGaD
Risedronate—Cough—Doxorubicin—prostate cancer	6.49e-05	0.000163	CcSEcCtD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—HPGDS—prostate cancer	6.46e-05	0.000506	CbGpPWpGaD
Risedronate—Shock—Epirubicin—prostate cancer	6.45e-05	0.000162	CcSEcCtD
Risedronate—Diarrhoea—Capecitabine—prostate cancer	6.44e-05	0.000162	CcSEcCtD
Risedronate—FDPS—Metabolism—PPARA—prostate cancer	6.43e-05	0.000504	CbGpPWpGaD
Risedronate—Nervous system disorder—Epirubicin—prostate cancer	6.43e-05	0.000162	CcSEcCtD
Risedronate—Dizziness—Docetaxel—prostate cancer	6.43e-05	0.000162	CcSEcCtD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—CYP2C19—prostate cancer	6.42e-05	0.000502	CbGpPWpGaD
Risedronate—Hypertension—Doxorubicin—prostate cancer	6.42e-05	0.000161	CcSEcCtD
Risedronate—Skin disorder—Epirubicin—prostate cancer	6.37e-05	0.00016	CcSEcCtD
Risedronate—Chest pain—Doxorubicin—prostate cancer	6.33e-05	0.000159	CcSEcCtD
Risedronate—Arthralgia—Doxorubicin—prostate cancer	6.33e-05	0.000159	CcSEcCtD
Risedronate—Myalgia—Doxorubicin—prostate cancer	6.33e-05	0.000159	CcSEcCtD
Risedronate—Anxiety—Doxorubicin—prostate cancer	6.31e-05	0.000158	CcSEcCtD
Risedronate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	6.28e-05	0.000158	CcSEcCtD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—MAP2K1—prostate cancer	6.28e-05	0.000491	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—HSD17B1—prostate cancer	6.27e-05	0.00049	CbGpPWpGaD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—ACHE—prostate cancer	6.27e-05	0.00049	CbGpPWpGaD
Risedronate—Dizziness—Capecitabine—prostate cancer	6.22e-05	0.000156	CcSEcCtD
Risedronate—Dry mouth—Doxorubicin—prostate cancer	6.19e-05	0.000155	CcSEcCtD
Risedronate—Vomiting—Docetaxel—prostate cancer	6.18e-05	0.000155	CcSEcCtD
Risedronate—Hypersensitivity—Prednisone—prostate cancer	6.18e-05	0.000155	CcSEcCtD
Risedronate—Rash—Docetaxel—prostate cancer	6.13e-05	0.000154	CcSEcCtD
Risedronate—Dermatitis—Docetaxel—prostate cancer	6.12e-05	0.000154	CcSEcCtD
Risedronate—Headache—Docetaxel—prostate cancer	6.09e-05	0.000153	CcSEcCtD
Risedronate—FDPS—Metabolism—CAV1—prostate cancer	6.05e-05	0.000473	CbGpPWpGaD
Risedronate—Infection—Doxorubicin—prostate cancer	6.03e-05	0.000151	CcSEcCtD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—AKR1C3—prostate cancer	6.02e-05	0.000471	CbGpPWpGaD
Risedronate—Asthenia—Prednisone—prostate cancer	6.01e-05	0.000151	CcSEcCtD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—PRKACB—prostate cancer	5.99e-05	0.000469	CbGpPWpGaD
Risedronate—Vomiting—Capecitabine—prostate cancer	5.98e-05	0.00015	CcSEcCtD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—FGF2—prostate cancer	5.97e-05	0.000467	CbGpPWpGaD
Risedronate—Musculoskeletal discomfort—Epirubicin—prostate cancer	5.97e-05	0.00015	CcSEcCtD
Risedronate—Shock—Doxorubicin—prostate cancer	5.97e-05	0.00015	CcSEcCtD
Risedronate—Nervous system disorder—Doxorubicin—prostate cancer	5.95e-05	0.000149	CcSEcCtD
Risedronate—PTGS2—Disease—WNT4—prostate cancer	5.94e-05	0.000465	CbGpPWpGaD
Risedronate—Rash—Capecitabine—prostate cancer	5.93e-05	0.000149	CcSEcCtD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—CYP17A1—prostate cancer	5.93e-05	0.000464	CbGpPWpGaD
Risedronate—Pruritus—Prednisone—prostate cancer	5.93e-05	0.000149	CcSEcCtD
Risedronate—Insomnia—Epirubicin—prostate cancer	5.93e-05	0.000149	CcSEcCtD
Risedronate—Dermatitis—Capecitabine—prostate cancer	5.93e-05	0.000149	CcSEcCtD
Risedronate—Headache—Capecitabine—prostate cancer	5.9e-05	0.000148	CcSEcCtD
Risedronate—Skin disorder—Doxorubicin—prostate cancer	5.89e-05	0.000148	CcSEcCtD
Risedronate—Paraesthesia—Epirubicin—prostate cancer	5.89e-05	0.000148	CcSEcCtD
Risedronate—Dyspnoea—Epirubicin—prostate cancer	5.84e-05	0.000147	CcSEcCtD
Risedronate—FDPS—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	5.78e-05	0.000452	CbGpPWpGaD
Risedronate—Nausea—Docetaxel—prostate cancer	5.77e-05	0.000145	CcSEcCtD
Risedronate—Dyspepsia—Epirubicin—prostate cancer	5.77e-05	0.000145	CcSEcCtD
Risedronate—PTGS2—Spinal Cord Injury—MYC—prostate cancer	5.74e-05	0.000449	CbGpPWpGaD
Risedronate—Diarrhoea—Prednisone—prostate cancer	5.74e-05	0.000144	CcSEcCtD
Risedronate—PTGS2—Spinal Cord Injury—TGFB1—prostate cancer	5.73e-05	0.000448	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—BCL2—prostate cancer	5.67e-05	0.000444	CbGpPWpGaD
Risedronate—Gastrointestinal disorder—Epirubicin—prostate cancer	5.66e-05	0.000142	CcSEcCtD
Risedronate—Fatigue—Epirubicin—prostate cancer	5.65e-05	0.000142	CcSEcCtD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—NCOA2—prostate cancer	5.65e-05	0.000442	CbGpPWpGaD
Risedronate—PTGS2—Spinal Cord Injury—EGFR—prostate cancer	5.61e-05	0.000439	CbGpPWpGaD
Risedronate—Pain—Epirubicin—prostate cancer	5.61e-05	0.000141	CcSEcCtD
Risedronate—Constipation—Epirubicin—prostate cancer	5.61e-05	0.000141	CcSEcCtD
Risedronate—Nausea—Capecitabine—prostate cancer	5.59e-05	0.00014	CcSEcCtD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—MDM2—prostate cancer	5.59e-05	0.000437	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—B4GALT4—prostate cancer	5.58e-05	0.000437	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—HPGD—prostate cancer	5.58e-05	0.000437	CbGpPWpGaD
Risedronate—Dizziness—Prednisone—prostate cancer	5.54e-05	0.000139	CcSEcCtD
Risedronate—Musculoskeletal discomfort—Doxorubicin—prostate cancer	5.53e-05	0.000139	CcSEcCtD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—prostate cancer	5.51e-05	0.000431	CbGpPWpGaD
Risedronate—FDPS—Metabolism—PIK3CG—prostate cancer	5.51e-05	0.000431	CbGpPWpGaD
Risedronate—Insomnia—Doxorubicin—prostate cancer	5.49e-05	0.000138	CcSEcCtD
Risedronate—PTGS2—Selenium Micronutrient Network—IL6—prostate cancer	5.46e-05	0.000427	CbGpPWpGaD
Risedronate—Paraesthesia—Doxorubicin—prostate cancer	5.45e-05	0.000137	CcSEcCtD
Risedronate—Dyspnoea—Doxorubicin—prostate cancer	5.41e-05	0.000136	CcSEcCtD
Risedronate—Gastrointestinal pain—Epirubicin—prostate cancer	5.36e-05	0.000135	CcSEcCtD
Risedronate—Dyspepsia—Doxorubicin—prostate cancer	5.34e-05	0.000134	CcSEcCtD
Risedronate—PTGS2—Disease—LDHB—prostate cancer	5.33e-05	0.000417	CbGpPWpGaD
Risedronate—PTGS2—Disease—RPL12—prostate cancer	5.33e-05	0.000417	CbGpPWpGaD
Risedronate—Vomiting—Prednisone—prostate cancer	5.33e-05	0.000134	CcSEcCtD
Risedronate—Rash—Prednisone—prostate cancer	5.29e-05	0.000133	CcSEcCtD
Risedronate—Dermatitis—Prednisone—prostate cancer	5.28e-05	0.000133	CcSEcCtD
Risedronate—Headache—Prednisone—prostate cancer	5.25e-05	0.000132	CcSEcCtD
Risedronate—PTGS2—Metabolism—TNFRSF21—prostate cancer	5.25e-05	0.000411	CbGpPWpGaD
Risedronate—Gastrointestinal disorder—Doxorubicin—prostate cancer	5.24e-05	0.000132	CcSEcCtD
Risedronate—Fatigue—Doxorubicin—prostate cancer	5.23e-05	0.000131	CcSEcCtD
Risedronate—FDPS—Metabolism—INS—prostate cancer	5.22e-05	0.000408	CbGpPWpGaD
Risedronate—Urticaria—Epirubicin—prostate cancer	5.21e-05	0.000131	CcSEcCtD
Risedronate—Constipation—Doxorubicin—prostate cancer	5.19e-05	0.00013	CcSEcCtD
Risedronate—Pain—Doxorubicin—prostate cancer	5.19e-05	0.00013	CcSEcCtD
Risedronate—Abdominal pain—Epirubicin—prostate cancer	5.18e-05	0.00013	CcSEcCtD
Risedronate—Body temperature increased—Epirubicin—prostate cancer	5.18e-05	0.00013	CcSEcCtD
Risedronate—FDPS—Metabolism—CREBBP—prostate cancer	5.11e-05	0.0004	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—MTAP—prostate cancer	5.11e-05	0.0004	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—CYP7B1—prostate cancer	5.11e-05	0.0004	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1B—prostate cancer	5.1e-05	0.000399	CbGpPWpGaD
Risedronate—PTGS2—Disease—TCN2—prostate cancer	5.05e-05	0.000395	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—prostate cancer	5e-05	0.000391	CbGpPWpGaD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—CYP1B1—prostate cancer	4.99e-05	0.000391	CbGpPWpGaD
Risedronate—Nausea—Prednisone—prostate cancer	4.98e-05	0.000125	CcSEcCtD
Risedronate—PTGS2—Metabolism—SULT1E1—prostate cancer	4.98e-05	0.00039	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—SRD5A1—prostate cancer	4.98e-05	0.00039	CbGpPWpGaD
Risedronate—Gastrointestinal pain—Doxorubicin—prostate cancer	4.96e-05	0.000125	CcSEcCtD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—prostate cancer	4.87e-05	0.000381	CbGpPWpGaD
Risedronate—FDPS—Metabolism—PIK3CD—prostate cancer	4.84e-05	0.000379	CbGpPWpGaD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—GGT1—prostate cancer	4.84e-05	0.000378	CbGpPWpGaD
Risedronate—Hypersensitivity—Epirubicin—prostate cancer	4.83e-05	0.000121	CcSEcCtD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—prostate cancer	4.82e-05	0.000377	CbGpPWpGaD
Risedronate—Urticaria—Doxorubicin—prostate cancer	4.82e-05	0.000121	CcSEcCtD
Risedronate—Body temperature increased—Doxorubicin—prostate cancer	4.8e-05	0.00012	CcSEcCtD
Risedronate—Abdominal pain—Doxorubicin—prostate cancer	4.8e-05	0.00012	CcSEcCtD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—NCOA1—prostate cancer	4.76e-05	0.000373	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—ACSL4—prostate cancer	4.75e-05	0.000372	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—HSD17B3—prostate cancer	4.75e-05	0.000372	CbGpPWpGaD
Risedronate—PTGS2—Spinal Cord Injury—TP53—prostate cancer	4.71e-05	0.000369	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—prostate cancer	4.71e-05	0.000369	CbGpPWpGaD
Risedronate—Asthenia—Epirubicin—prostate cancer	4.7e-05	0.000118	CcSEcCtD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—prostate cancer	4.7e-05	0.000368	CbGpPWpGaD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—CYP19A1—prostate cancer	4.69e-05	0.000367	CbGpPWpGaD
Risedronate—Pruritus—Epirubicin—prostate cancer	4.64e-05	0.000117	CcSEcCtD
Risedronate—FDPS—Metabolism—NOS3—prostate cancer	4.57e-05	0.000358	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—ARG2—prostate cancer	4.55e-05	0.000356	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—PHGDH—prostate cancer	4.55e-05	0.000356	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—UMPS—prostate cancer	4.55e-05	0.000356	CbGpPWpGaD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—RXRA—prostate cancer	4.53e-05	0.000354	CbGpPWpGaD
Risedronate—Diarrhoea—Epirubicin—prostate cancer	4.49e-05	0.000113	CcSEcCtD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—prostate cancer	4.48e-05	0.000351	CbGpPWpGaD
Risedronate—Hypersensitivity—Doxorubicin—prostate cancer	4.47e-05	0.000112	CcSEcCtD
Risedronate—PTGS2—Metabolism—LDHB—prostate cancer	4.46e-05	0.000349	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—CYP3A5—prostate cancer	4.38e-05	0.000343	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—SRC—prostate cancer	4.36e-05	0.000341	CbGpPWpGaD
Risedronate—Asthenia—Doxorubicin—prostate cancer	4.35e-05	0.000109	CcSEcCtD
Risedronate—Dizziness—Epirubicin—prostate cancer	4.34e-05	0.000109	CcSEcCtD
Risedronate—PTGS2—Spinal Cord Injury—IL6—prostate cancer	4.32e-05	0.000338	CbGpPWpGaD
Risedronate—PTGS2—Disease—GSTO1—prostate cancer	4.3e-05	0.000336	CbGpPWpGaD
Risedronate—Pruritus—Doxorubicin—prostate cancer	4.29e-05	0.000108	CcSEcCtD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—prostate cancer	4.24e-05	0.000332	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—PDHA1—prostate cancer	4.23e-05	0.000331	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—GSTA3—prostate cancer	4.23e-05	0.000331	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—TCN2—prostate cancer	4.23e-05	0.000331	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—UCP3—prostate cancer	4.23e-05	0.000331	CbGpPWpGaD
Risedronate—FDPS—Metabolism—PIK3CB—prostate cancer	4.22e-05	0.00033	CbGpPWpGaD
Risedronate—FDPS—Metabolism—PTGS2—prostate cancer	4.18e-05	0.000327	CbGpPWpGaD
Risedronate—Vomiting—Epirubicin—prostate cancer	4.17e-05	0.000105	CcSEcCtD
Risedronate—Diarrhoea—Doxorubicin—prostate cancer	4.15e-05	0.000104	CcSEcCtD
Risedronate—Rash—Epirubicin—prostate cancer	4.13e-05	0.000104	CcSEcCtD
Risedronate—Dermatitis—Epirubicin—prostate cancer	4.13e-05	0.000104	CcSEcCtD
Risedronate—PTGS2—Disease—LRP2—prostate cancer	4.12e-05	0.000322	CbGpPWpGaD
Risedronate—Headache—Epirubicin—prostate cancer	4.11e-05	0.000103	CcSEcCtD
Risedronate—PTGS2—Disease—RPL10—prostate cancer	4.04e-05	0.000316	CbGpPWpGaD
Risedronate—PTGS2—Disease—P4HB—prostate cancer	4.04e-05	0.000316	CbGpPWpGaD
Risedronate—PTGS2—Disease—EIF2AK2—prostate cancer	4.04e-05	0.000316	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—HSD3B1—prostate cancer	4.04e-05	0.000316	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—SLC22A3—prostate cancer	4.04e-05	0.000316	CbGpPWpGaD
Risedronate—Dizziness—Doxorubicin—prostate cancer	4.01e-05	0.000101	CcSEcCtD
Risedronate—PTGS2—Disease—HIST1H2BG—prostate cancer	3.97e-05	0.00031	CbGpPWpGaD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—LPL—prostate cancer	3.92e-05	0.000307	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—prostate cancer	3.91e-05	0.000306	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—prostate cancer	3.9e-05	0.000305	CbGpPWpGaD
Risedronate—Nausea—Epirubicin—prostate cancer	3.89e-05	9.78e-05	CcSEcCtD
Risedronate—PTGS2—Metabolism—GSTA4—prostate cancer	3.87e-05	0.000303	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—TBXAS1—prostate cancer	3.87e-05	0.000303	CbGpPWpGaD
Risedronate—Vomiting—Doxorubicin—prostate cancer	3.86e-05	9.69e-05	CcSEcCtD
Risedronate—PTGS2—Disease—HIST1H4H—prostate cancer	3.83e-05	0.0003	CbGpPWpGaD
Risedronate—PTGS2—Disease—NPPA—prostate cancer	3.83e-05	0.0003	CbGpPWpGaD
Risedronate—Rash—Doxorubicin—prostate cancer	3.82e-05	9.61e-05	CcSEcCtD
Risedronate—Dermatitis—Doxorubicin—prostate cancer	3.82e-05	9.6e-05	CcSEcCtD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—prostate cancer	3.82e-05	0.000299	CbGpPWpGaD
Risedronate—Headache—Doxorubicin—prostate cancer	3.8e-05	9.55e-05	CcSEcCtD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—CYP1A1—prostate cancer	3.78e-05	0.000296	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—GSTA2—prostate cancer	3.77e-05	0.000295	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—SULT1A1—prostate cancer	3.73e-05	0.000292	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—ABCG5—prostate cancer	3.73e-05	0.000292	CbGpPWpGaD
Risedronate—FDPS—Metabolism—PTEN—prostate cancer	3.65e-05	0.000286	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—GSTA1—prostate cancer	3.64e-05	0.000285	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—prostate cancer	3.61e-05	0.000282	CbGpPWpGaD
Risedronate—Nausea—Doxorubicin—prostate cancer	3.6e-05	9.05e-05	CcSEcCtD
Risedronate—PTGS2—Metabolism—NAT2—prostate cancer	3.6e-05	0.000282	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—GSTO1—prostate cancer	3.6e-05	0.000282	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—HSD3B2—prostate cancer	3.6e-05	0.000282	CbGpPWpGaD
Risedronate—FDPS—Metabolism—EP300—prostate cancer	3.48e-05	0.000272	CbGpPWpGaD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—PPARA—prostate cancer	3.46e-05	0.000271	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—PLCB2—prostate cancer	3.45e-05	0.00027	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—LRP2—prostate cancer	3.45e-05	0.00027	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—CYP2C18—prostate cancer	3.45e-05	0.00027	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—P4HB—prostate cancer	3.38e-05	0.000265	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—prostate cancer	3.32e-05	0.000259	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—SLC22A1—prostate cancer	3.29e-05	0.000258	CbGpPWpGaD
Risedronate—PTGS2—Disease—TGFBR1—prostate cancer	3.26e-05	0.000255	CbGpPWpGaD
Risedronate—PTGS2—Disease—B2M—prostate cancer	3.26e-05	0.000255	CbGpPWpGaD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—CAV1—prostate cancer	3.25e-05	0.000255	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—SULT2A1—prostate cancer	3.21e-05	0.000251	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—prostate cancer	3.21e-05	0.000251	CbGpPWpGaD
Risedronate—PTGS2—Disease—RPS19—prostate cancer	3.2e-05	0.000251	CbGpPWpGaD
Risedronate—PTGS2—Disease—AKR1C3—prostate cancer	3.2e-05	0.000251	CbGpPWpGaD
Risedronate—PTGS2—Disease—PRKACB—prostate cancer	3.19e-05	0.000249	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—MED12—prostate cancer	3.16e-05	0.000247	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—GNG5—prostate cancer	3.13e-05	0.000245	CbGpPWpGaD
Risedronate—PTGS2—Disease—PPP3CA—prostate cancer	3.11e-05	0.000243	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—NCOA3—prostate cancer	3.02e-05	0.000236	CbGpPWpGaD
Risedronate—PTGS2—Disease—PRKCZ—prostate cancer	3.01e-05	0.000235	CbGpPWpGaD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	2.96e-05	0.000232	CbGpPWpGaD
Risedronate—PTGS2—Disease—CALR—prostate cancer	2.95e-05	0.000231	CbGpPWpGaD
Risedronate—PTGS2—Disease—FGFR4—prostate cancer	2.9e-05	0.000227	CbGpPWpGaD
Risedronate—PTGS2—Disease—PARP1—prostate cancer	2.9e-05	0.000227	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—HPGDS—prostate cancer	2.88e-05	0.000225	CbGpPWpGaD
Risedronate—PTGS2—Disease—CALCA—prostate cancer	2.87e-05	0.000224	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—CYP2C19—prostate cancer	2.86e-05	0.000224	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—GSTT1—prostate cancer	2.79e-05	0.000218	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—ACHE—prostate cancer	2.79e-05	0.000218	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—CYP2A6—prostate cancer	2.76e-05	0.000216	CbGpPWpGaD
Risedronate—PTGS2—Disease—HSPA1A—prostate cancer	2.75e-05	0.000215	CbGpPWpGaD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	2.75e-05	0.000215	CbGpPWpGaD
Risedronate—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—prostate cancer	2.71e-05	0.000212	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—AKR1C3—prostate cancer	2.68e-05	0.00021	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—PRKACB—prostate cancer	2.67e-05	0.000209	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—CYP17A1—prostate cancer	2.64e-05	0.000207	CbGpPWpGaD
Risedronate—PTGS2—Disease—CASP9—prostate cancer	2.64e-05	0.000206	CbGpPWpGaD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	2.61e-05	0.000204	CbGpPWpGaD
Risedronate—FDPS—Metabolism—PIK3CA—prostate cancer	2.57e-05	0.000201	CbGpPWpGaD
Risedronate—PTGS2—Disease—PRKCQ—prostate cancer	2.56e-05	0.0002	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—NCOA2—prostate cancer	2.52e-05	0.000197	CbGpPWpGaD
Risedronate—PTGS2—Disease—FGF10—prostate cancer	2.43e-05	0.00019	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—SLC5A5—prostate cancer	2.4e-05	0.000188	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—CYP2E1—prostate cancer	2.35e-05	0.000184	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—NQO1—prostate cancer	2.32e-05	0.000181	CbGpPWpGaD
Risedronate—PTGS2—Disease—TGFBR2—prostate cancer	2.31e-05	0.000181	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—TH—prostate cancer	2.29e-05	0.000179	CbGpPWpGaD
Risedronate—PTGS2—Disease—ITPR1—prostate cancer	2.27e-05	0.000178	CbGpPWpGaD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	2.27e-05	0.000178	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—CYP3A4—prostate cancer	2.26e-05	0.000177	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—CYP1B1—prostate cancer	2.22e-05	0.000174	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—GGT1—prostate cancer	2.15e-05	0.000169	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—NCOA1—prostate cancer	2.12e-05	0.000166	CbGpPWpGaD
Risedronate—FDPS—Metabolism—AKT1—prostate cancer	2.1e-05	0.000165	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—CYP19A1—prostate cancer	2.09e-05	0.000164	CbGpPWpGaD
Risedronate—PTGS2—Disease—LPL—prostate cancer	2.08e-05	0.000163	CbGpPWpGaD
Risedronate—PTGS2—Disease—PDGFRB—prostate cancer	2.06e-05	0.000162	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—RXRA—prostate cancer	2.02e-05	0.000158	CbGpPWpGaD
Risedronate—PTGS2—Disease—ERCC2—prostate cancer	2e-05	0.000156	CbGpPWpGaD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	1.96e-05	0.000154	CbGpPWpGaD
Risedronate—PTGS2—Disease—ERBB3—prostate cancer	1.95e-05	0.000153	CbGpPWpGaD
Risedronate—PTGS2—Disease—FGFR2—prostate cancer	1.95e-05	0.000152	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—COMT—prostate cancer	1.94e-05	0.000152	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—GSTP1—prostate cancer	1.93e-05	0.000151	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—ITPR1—prostate cancer	1.9e-05	0.000149	CbGpPWpGaD
Risedronate—PTGS2—Disease—MTHFR—prostate cancer	1.88e-05	0.000147	CbGpPWpGaD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—EP300—prostate cancer	1.87e-05	0.000146	CbGpPWpGaD
Risedronate—PTGS2—Disease—TERT—prostate cancer	1.87e-05	0.000146	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—TYMS—prostate cancer	1.8e-05	0.000141	CbGpPWpGaD
Risedronate—PTGS2—Disease—HIF1A—prostate cancer	1.79e-05	0.00014	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—GSTM1—prostate cancer	1.78e-05	0.000139	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—LPL—prostate cancer	1.74e-05	0.000137	CbGpPWpGaD
Risedronate—PTGS2—Disease—CAV1—prostate cancer	1.73e-05	0.000135	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—CYP1A1—prostate cancer	1.68e-05	0.000132	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—ERCC2—prostate cancer	1.67e-05	0.000131	CbGpPWpGaD
Risedronate—PTGS2—Disease—BAD—prostate cancer	1.63e-05	0.000127	CbGpPWpGaD
Risedronate—PTGS2—Disease—APC—prostate cancer	1.58e-05	0.000123	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—MTHFR—prostate cancer	1.57e-05	0.000123	CbGpPWpGaD
Risedronate—PTGS2—Disease—EGF—prostate cancer	1.56e-05	0.000122	CbGpPWpGaD
Risedronate—PTGS2—Disease—IRS1—prostate cancer	1.56e-05	0.000122	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—PPARA—prostate cancer	1.54e-05	0.000121	CbGpPWpGaD
Risedronate—PTGS2—Disease—GSK3B—prostate cancer	1.51e-05	0.000118	CbGpPWpGaD
Risedronate—PTGS2—Disease—INS—prostate cancer	1.49e-05	0.000117	CbGpPWpGaD
Risedronate—PTGS2—Disease—CREBBP—prostate cancer	1.46e-05	0.000114	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—CAV1—prostate cancer	1.45e-05	0.000113	CbGpPWpGaD
Risedronate—PTGS2—Disease—MAP2K1—prostate cancer	1.39e-05	0.000109	CbGpPWpGaD
Risedronate—PTGS2—Disease—PIK3CD—prostate cancer	1.39e-05	0.000108	CbGpPWpGaD
Risedronate—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.38e-05	0.000108	CbGpPWpGaD
Risedronate—PTGS2—Disease—SERPINE1—prostate cancer	1.37e-05	0.000107	CbGpPWpGaD
Risedronate—PTGS2—Disease—FGF2—prostate cancer	1.33e-05	0.000104	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—PIK3CG—prostate cancer	1.32e-05	0.000103	CbGpPWpGaD
Risedronate—PTGS2—Disease—NOS3—prostate cancer	1.31e-05	0.000102	CbGpPWpGaD
Risedronate—PTGS2—Disease—JAK2—prostate cancer	1.27e-05	9.95e-05	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—INS—prostate cancer	1.25e-05	9.78e-05	CbGpPWpGaD
Risedronate—PTGS2—Disease—MDM2—prostate cancer	1.24e-05	9.71e-05	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—CREBBP—prostate cancer	1.22e-05	9.58e-05	CbGpPWpGaD
Risedronate—PTGS2—Disease—ERBB2—prostate cancer	1.22e-05	9.58e-05	CbGpPWpGaD
Risedronate—PTGS2—Disease—PIK3CB—prostate cancer	1.21e-05	9.45e-05	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—PIK3CD—prostate cancer	1.16e-05	9.08e-05	CbGpPWpGaD
Risedronate—PTGS2—Disease—CDKN1B—prostate cancer	1.13e-05	8.87e-05	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—NOS3—prostate cancer	1.1e-05	8.57e-05	CbGpPWpGaD
Risedronate—PTGS2—Disease—CTNNB1—prostate cancer	1.07e-05	8.38e-05	CbGpPWpGaD
Risedronate—PTGS2—Disease—CDKN1A—prostate cancer	1.05e-05	8.18e-05	CbGpPWpGaD
Risedronate—PTGS2—Disease—PTEN—prostate cancer	1.04e-05	8.17e-05	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—PIK3CB—prostate cancer	1.01e-05	7.91e-05	CbGpPWpGaD
Risedronate—PTGS2—Disease—EP300—prostate cancer	9.95e-06	7.79e-05	CbGpPWpGaD
Risedronate—PTGS2—Disease—SRC—prostate cancer	9.68e-06	7.57e-05	CbGpPWpGaD
Risedronate—PTGS2—Disease—STAT3—prostate cancer	9.33e-06	7.3e-05	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—PTEN—prostate cancer	8.74e-06	6.84e-05	CbGpPWpGaD
Risedronate—PTGS2—Disease—MYC—prostate cancer	8.67e-06	6.79e-05	CbGpPWpGaD
Risedronate—PTGS2—Disease—TGFB1—prostate cancer	8.65e-06	6.77e-05	CbGpPWpGaD
Risedronate—PTGS2—Disease—EGFR—prostate cancer	8.48e-06	6.64e-05	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—EP300—prostate cancer	8.33e-06	6.52e-05	CbGpPWpGaD
Risedronate—PTGS2—Disease—KRAS—prostate cancer	8.01e-06	6.27e-05	CbGpPWpGaD
Risedronate—PTGS2—Disease—PIK3CA—prostate cancer	7.36e-06	5.76e-05	CbGpPWpGaD
Risedronate—PTGS2—Disease—IL6—prostate cancer	6.52e-06	5.1e-05	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—PIK3CA—prostate cancer	6.16e-06	4.82e-05	CbGpPWpGaD
Risedronate—PTGS2—Disease—AKT1—prostate cancer	6.01e-06	4.71e-05	CbGpPWpGaD
Risedronate—PTGS2—Metabolism—AKT1—prostate cancer	5.04e-06	3.94e-05	CbGpPWpGaD
